Vigmed granted additional patent in the US.

The US Patent and Trademark office has announced to Vigmed that it intends to
grant the Company an additional patent for their needle protecting
solution found in the product lines CLiP® and SWiTCH®.
Vigmed has earlier been granted patents for the needle protecting
solution CLiP®, and systems comprising CLiP®. This patent will broaden Vigmed’s
scope of protection, and additionally give the Company protection for another
feature of CLiP® and SWiTCH®.

Vigmed has filed, nationally and internationally, more than 80 patents and
patent applications based on more than three innovation platforms. The company
owns all its patents and patent applications without any restrictions. The basic
patents all have a maximum validity period.

Vigmed’s strategy is to protect the Company's technology and products in all
geographical areas deemed to be of importance. Vigmed intends to expand its
patent portfolio continuously on both the offensive and defensive patent and
utility model rights based on a number of new innovation platforms.
For further information contact:

CEO Henrik Olsen, +46 42 600 5320 or R&D Director Fredrik Thörne, +46 42 600
5312
Vigmed är ett svenskt medicinteknologiskt bolag vars mission är att eliminera
nålssticksskador och risken för smittspridning av farliga blodburna
infektionssjukdomar genom att erbjuda marknaden unika nålskyddade
stickprodukter. Vigmed har sitt huvudkontor i Helsingborg. Vigmeds aktie handlas
på NASDAQ OMX First North under kortnamnet VIG och har cirka 5 600 aktieägare.
Remium Nordic AB är bolagets Certified Advisor. Ytterligare information om
bolaget återfinns på Vigmeds hemsida: www.vigmed.com/investor